AbCellera Biologics (NASDAQ:ABCL – Get Free Report) and Pluri (NASDAQ:PLUR – Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations and earnings.
Volatility & Risk
AbCellera Biologics has a beta of 1.59, indicating that its share price is 59% more volatile than the S&P 500. Comparatively, Pluri has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500.
Earnings & Valuation
This table compares AbCellera Biologics and Pluri”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| AbCellera Biologics | $75.13 million | 49.95 | -$146.41 million | ($0.48) | -23.94 |
| Pluri | $1.02 million | 12.98 | -$23.82 million | ($2.45) | -0.43 |
Pluri has lower revenue, but higher earnings than AbCellera Biologics. AbCellera Biologics is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of recent recommendations and price targets for AbCellera Biologics and Pluri, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| AbCellera Biologics | 1 | 1 | 7 | 2 | 2.91 |
| Pluri | 1 | 0 | 0 | 0 | 1.00 |
AbCellera Biologics presently has a consensus target price of $16.20, indicating a potential upside of 40.99%. Given AbCellera Biologics’ stronger consensus rating and higher probable upside, research analysts clearly believe AbCellera Biologics is more favorable than Pluri.
Insider & Institutional Ownership
61.4% of AbCellera Biologics shares are owned by institutional investors. Comparatively, 16.6% of Pluri shares are owned by institutional investors. 28.4% of AbCellera Biologics shares are owned by insiders. Comparatively, 43.2% of Pluri shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Profitability
This table compares AbCellera Biologics and Pluri’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| AbCellera Biologics | -218.54% | -15.35% | -10.84% |
| Pluri | -1,943.87% | N/A | -104.36% |
Summary
AbCellera Biologics beats Pluri on 11 of the 15 factors compared between the two stocks.
About AbCellera Biologics
AbCellera Biologics Inc. is a biotechnology company headquartered in Vancouver, Canada. It discovers and develops antibody-based medicines, using laboratory and computational tools to identify and optimize antibodies that may be developed into treatments for disease. The company works with pharmaceutical and biotechnology partners on antibody discovery and drug development, while also advancing a portfolio of its own therapeutic candidates. Its work spans early-stage research through preclinical and clinical development, with programs focused on areas including cancer and immune-related diseases.
About Pluri
Pluri Ltd. is an Israel-based biotechnology company developing cell-based products and technologies. Its therapeutic research centers on PLX cells, derived from human placental tissue and expanded using the company’s cell-manufacturing platform. Pluri has investigated these cells for potential use in a range of medical conditions; its therapies remain in development. The company also applies its cell-expansion technology to areas beyond medicine, including food technology and agriculture, where it is exploring cell-based products and production methods.
Receive News & Ratings for AbCellera Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbCellera Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
